Alzheimer S Disease Advances For A New Century

This volume is a companion to the highly successful book published in association with the Journal of Alzheimer's Disease (JAD) on the centennial of Alzheimer's discovery: "Alzheimer's Disease: A Century of Scientific and Clinical Research". Instead of looking back, this collection, "Alzheimer's Disease: Advances for a New Century", will look forward. Using scientometric analysis the most promising developments since the Alzheimer Centennial in 2006 have been substantiated. While prior trends and advances in genetics, amyloid-β, tau, neuropathology, and oxidative stress continue as active areas, emergent areas impacting the transition from normal cognition to Alzheimer's disease such as diagnostic imaging, biomarkers, metabolism, and lifestyle (areas conceived only a few years ago) now dominate the debate.Invited contributors have summarized their landmark publications identified by our analysis and have put them into perspective, explaining the impetus behind the work, the contribution of the results to the field, and who played a role in the work.

This book examines every major aspect of Alzheimer disease at a time when there has been no scholarly research volume on the subject published in the last 3-5 years. This edition includes expanded coverage of the cellular-level exploration of related dementing disorders, with in-depth presentation of prion diseases, Pick's disease, fronto-temporal disorders, transgenic models, and biochemistry of presenilins.

Alzheimer's Disease: New Beginnings focuses on the future promise for therapeutic breakthroughs in light of notable clinical trial failures. The volume editors used a combination of scientometric evaluations to determine the most promising new approaches as well as soliciting insights from leaders in each of the major areas of Alzheimer's disease research. By combining these two approaches, they recruited authors from the entire outlook spectrum, from those who feel an elusive breakthrough might still be a few, well-placed tweaks away to those who feel that they are launching entirely new investigative paradigms. These scholars present an open-eyed path forward. Now is the most exciting period in this field as old dogmas make way for new insights, from new approaches to clinical trials, improved biomarker-based diagnostics, population-based studies, prevention, metabolism, to further refinement of the role of inflammation, genetics, tau, and amyloid-β.

This volume is a companion to the highly successful book published in association with the Journal of Alzheimer’s Disease (JAD) on the centennial of Alzheimer’s discovery: “Alzheimer’s Disease: A Century of Scientific and Clinical Research”. Instead of looking back, this collection, “Alzheimer’s Disease: Advances for a New Century”, will look forward. Using scientometric analysis the most promising developments since the Alzheimer Centennial in 2006 have been substantiated. While prior trends and advances in genetics, amyloid-?, tau, neuropathology, and oxidative stress continue as active areas, emergent areas impacting the transition from normal cognition to Alzheimer’s disease such as diagnostic imaging, biomarkers, metabolism, and lifestyle (areas conceived only a few years ago) now dominate the debate. Invited contributors have summarized their landmark publications identified by our analysis and have put them into perspective, explaining the impetus behind the work, the contribution of the results to the field, and who played a role in the work.

"This is the book edition of the Journal of Alzheimer's Disease, Volume 9, No.3 Supplement (2006)"--T.p. verso.

The book aims to present, educate and inform individuals about Alzheimer's disease in a comprehensive manner. Its scope ranges from the discovery of the disease, epidemiology and basic biological principles underlying it, to advanced stem cell therapies used in the treatment of Alzheimer's. It adopts a 'global' perspective on Alzheimer's disease, and include epidemiological data and science from countries around the world. Alzheimer's disease is a rapidly growing problem seen in every country around the world. This is the first and only comprehensive book to cover Alzheimer's disease, and includes the most updated literature and scientific progress in the field of dementia and Alzheimer's disease research. Most books on the market that focus on Alzheimer's disease are targeted at caregivers as practical advice on how to deal with loved ones with the disease. This book instead is a comprehensive and popular science book that can be read by anyone with an interest in learning more about the disease. Dr. Jefferson Chen MD, PhD, co-author, participated in the world's first surgical clinical trial using shunts to treat Alzheimer's disease. His first-hand involvement in a clinical trial for patients with Alzheimer's disease and experience treating Normal Pressure Hydrocephalus (NPH) which is commonly misdiagnosed as Alzheimer's disease lends a unique perspective. This book with appeal to a wide audience, regardless of their scientific or educational background.

It is almost 120 years since Alzheimer’s disease (AD) was first reported, and the concept of modifiable risk factors associated with the disease has been present from the outset. Thus, the idea of preventing AD is not new, with reference to strategies noted as early as the 1990s. This subfield of AD research has matured in recent years, with the number of modifiable risk factors – the AD preventome – rising from the 7 initially identified to the current 12, with an estimated contribution to dementia cases worldwide of about 40%. This book, the Handbook of Prevention and Alzheimer’s Disease, introduces physicians, scientists, and other stakeholders to this subfield of AD research. It investigates the AD preventome, which will continue to expand as the understanding of new factors and related biomarkers is refined. Optimizing this preventome leads to an improvement in overall brain health, an outcome which reduces the risk of developing AD and improves quality of life. The book goes on to examine other domains of prevention, from vascular risk factors to social engagement and from sleep health to spirituality. If the journey to end AD can be likened to a long and arduous challenge, understanding every possible part of the overall toolkit of approaches for disease prevention and intervention is essential. Together with its companion volume on intervention, the book provides a comprehensive overview of strategies for tackling Alzheimer’s disease, and will be of interest to all those working in the field. Cover illustration: White matter tracts showing sex differences in connectivity in men versus women as a function of increasing body mass index. Reprinted with permission from Rahmani F, Wang Q, McKay NS, Keefe S, Hantler N, Hornbeck R, Wang Y, Hassenstab J, Schindler S, Xiong C, Morris JC, Benzinger TLS, Raji CA. Sex-Specific Patterns of Body Mass Index Relationship with White Matter Connectivity. J Alzheimers Dis. 2022;86(4):1831-1848. doi: 10.3233/JAD-215329. PMID: 35180116; PMCID: PMC9108572.

It is almost 120 years since Alzheimer’s disease (AD) was first reported, and the concept of managing some of the modifiable risk factors associated with the disease has been present from the outset. Intervening to manage risk factors as a way of tackling AD is not new, but optimizing brain health as a way of minimizing risk and maximizing the potential benefits of revolutionary new treatments for AD is becoming increasingly important. This book, the Handbook of Intervention and Alzheimer’s Disease, presents 47 papers exploring factors which may either inspire or inform future treatment and clinical trials. While novel interventions such as anti-amyloid immunotherapy present great opportunities, they may also increase the risk of brain bleeds and edema, which in turn may lead to adverse clinical outcomes. Such adverse outcomes are demonstrably more likely to occur in persons with poor brain health, so improved management of the risk factors which make up the AD preventome will also minimize the risks associated with such novel therapies. The papers in this volume can therefore be thought of as offering insight into those factors that can optimize brain health or providing key insights into interventions which may achieve such outcomes. Together with its companion volume on prevention, the book provides a comprehensive overview of strategies for tackling Alzheimer’s disease, and will be of interest to all those working in the field. Cover illustration: Improved hypoperfusion (resolving blue colors) on ASL MRI Z-score maps superimposed on structural MRI scans at baseline and one year in a PET amyloid-positive research participant with cognitive complaints undergoing one year of multi-domain personalized brain health interventions (vascular disease management, dietary optimization, sustained physical activity etc.). Permission to use this figure was granted both by the study P.I. Dr. David Merrill, MD, PhD, of the Pacific Neuroscience Institute and the research participant.